How are analysts currently viewing SpaceX's stock? The outlook for SpaceX's stock is divided, showcasing a significant disparity among Wall Street analysts just a week after its public debut.
CFRA Research has initiated coverage of SpaceX with a Sell rating and a price target of $115 per share. This target is approximately 15% lower than the company's IPO price of $135 per share, indicating a cautious tone among some market analysts.
What explains the disparity in valuations? The contrasting opinions from analysts highlight a $75 gap between the most bullish and bearish views. Oppenheimer issued an Outperform rating with a price target of $190 on the eve of SpaceX’s Nasdaq debut. Meanwhile, New Street Research landed somewhat between those extremes with a target of $165. This gap indicates the lack of consensus in the market regarding SpaceX’s valuation, especially given its recent IPO.
What are the concerns voiced by analysts? CFRA analyst Keith Snyder bases his bearish stance on thorough research focused on three key aspects: the economic viability of Starlink’s broadband offerings, the capital requirements for the Starship development program, and SpaceX’s emerging ambitions in artificial intelligence. These factors are crucial in assessing the risks versus rewards of holding SpaceX shares.
The IPO was substantial, aiming for a valuation near $1.75 trillion, factoring in the 15% greenshoe option. Retail interest was notably high, with reported oversubscription exceeding $100 billion.
How does this impact investors in SpaceX? The bearish case raises essential points about valuation discipline, especially at a staggering valuation like $1.75 trillion. To justify such a price, SpaceX must execute flawlessly across its various, capital-intensive programs. Starship development costs are high, while Starlink’s economics, although showing signs of improvement, present challenges regarding long-term profitability.
Investors who acquired shares at the IPO price find themselves in a delicate position. With the stark difference between CFRA’s $115 target and Oppenheimer’s $190 forecast, they are caught between two conflicting perspectives of SpaceX’s future potential. Should Snyder's analysis resonate, those who bought at $135 face a considerable downside risk. Conversely, if the optimistic projections hold true, there exists a path for significant gains ahead of the initial offering price.